Asmar Roland, Safar Michel, Queneau Patrice
Cardiovascular Institute, Paris, France.
Drugs. 2003;63(10):927-32. doi: 10.2165/00003495-200363100-00001.
Epidemiological studies in the past decade have stressed the importance of pulse pressure (PP) as an independent risk factor for cardiovascular morbidity and mortality. We briefly review the epidemiological evidence and discuss the pathophysiological mechanisms which involve arterial stiffness and wave reflections in older patients. We discuss the therapeutic consequences of targeting PP rather than systolic (S) or diastolic (D) blood pressure (BP) when using antihypertensive agents. With this line of evidence it is important, first, to determine what minimal PP level indicates cardiovascular risk and, second, to note that an increasing number of clinical studies indicate that PP is poorly sensitive to placebo, while SBP and DBP are conversely highly sensitive. Finally, on the basis of large-scale intervention trials, PP seems to be an appropriate tool for studies of clinical pharmacology and therapeutics in the fields of hypertension, congestive heart failure and other cardiovascular diseases.
过去十年的流行病学研究强调了脉压(PP)作为心血管疾病发病率和死亡率独立危险因素的重要性。我们简要回顾流行病学证据,并讨论老年患者中涉及动脉僵硬度和波反射的病理生理机制。我们讨论在使用抗高血压药物时,以脉压而非收缩压(S)或舒张压(D)作为治疗靶点的治疗意义。基于这一系列证据,首先确定何种最低脉压水平表明存在心血管风险很重要,其次要注意越来越多的临床研究表明脉压对安慰剂反应不佳,而收缩压和舒张压则相反,对安慰剂高度敏感。最后,基于大规模干预试验,脉压似乎是高血压、充血性心力衰竭及其他心血管疾病领域临床药理学和治疗学研究的合适工具。